Osteoarthritis Pipeline Companies are CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others.
According to DelveInsight, over 100 companies are actively developing more than 110 therapies for Osteoarthritis.
Osteoarthritis Overview:
Osteoarthritis (OA) is the most common form of arthritis, often called “wear and tear” or degenerative joint disease, and primarily affects the knees, hips, and hands. In OA, the cartilage that cushions the ends of bones gradually wears away, and the underlying bone may undergo structural changes. These changes progress slowly and worsen over time. OA causes symptoms such as joint pain, stiffness, and swelling, and in severe cases, it can significantly limit mobility and disrupt daily activities. Typical signs include pain that worsens with activity and eases with rest, brief stiffness after periods of inactivity (usually under 30 minutes), a sense of joint instability, and sometimes a grinding or creaking sensation during movement. Swelling may also occur, particularly following prolonged joint use.
Download our report @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Osteoarthritis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Osteoarthritis Therapeutics Market.
Key Takeaways from the Osteoarthritis Pipeline Report
DelveInsight’s Osteoarthritis pipeline report highlights a vibrant landscape with over 100 companies developing more than 110 therapies for osteoarthritis.
Recent regulatory advancements include:
-
March 2025: Doron Therapeutics received RMAT designation for MOTYS, a biologic for knee osteoarthritis, accelerating its development and potential patient access.
-
December 2024: Genascence Corporation’s GNSC-001, a gene therapy for knee osteoarthritis, received Fast Track designation, reflecting its potential to provide long-term musculoskeletal relief.
-
October 2024: The FDA granted Fast Track designation to Sun Pharma’s MM-II, recognizing its promise in addressing unmet needs in osteoarthritis treatment.
Key companies advancing the osteoarthritis treatment landscape include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross, HiberCell, Bristol-Myers Squibb, Affimed, Wugen, Abivax, Glycostem, Synimmune, GT Biopharma, Bellicum, Asclepius, PersonGen, Chongqing Sidemu, Artiva, NKMax, Acepodia, Allife, Bright Path, Kuur Therapeutics, and others.
Promising pipeline candidates in various development stages include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, among others.
Osteoarthritis Pipeline Analysis
The Osteoarthritis pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Osteoarthritis Market.
-
Categorizes Osteoarthritis therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Osteoarthritis drugs under development based on:
-
Stage of development
-
Osteoarthritis Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Osteoarthritis Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Osteoarthritis Licensing agreements
-
Funding and investment activities supporting future Osteoarthritis market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Osteoarthritis Emerging Drugs
-
Lorecivivint: Biosplice Therapeutics
-
EP-104IAR: Eupraxia Pharmaceuticals
-
DFV890: Novartis
-
4P004: 4P-Pharma
-
GNSC 001: Genascence
Osteoarthritis Companies
Over 100 leading companies are actively developing therapies for Osteoarthritis, with Biosplice Therapeutics advancing a candidate into the Phase III stage.
DelveInsight’s report covers around 110+ products under different phases of Osteoarthritis clinical trials like
-
Osteoarthritis Late stage Therapies (Phase III)
-
Osteoarthritis Mid-stage Therapies (Phase II)
-
Osteoarthritis Early-stage Therapies (Phase I)
-
Osteoarthritis Pre-clinical and Osteoarthritis Discovery stage Therapies
-
Osteoarthritis Discontinued & Inactive Therapies
Osteoarthritis pipeline report provides the Osteoarthritis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Osteoarthritis Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Osteoarthritis Therapies and Key Osteoarthritis Companies: Osteoarthritis Clinical Trials and recent advancements
Osteoarthritis Pipeline Therapeutic Assessment
• Osteoarthritis Assessment by Product Type
• Osteoarthritis By Stage
• Osteoarthritis Assessment by Route of Administration
• Osteoarthritis Assessment by Molecule Type
Download Osteoarthritis Sample report to know in detail about the Osteoarthritis treatment market @ Osteoarthritis Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Osteoarthritis Current Treatment Patterns
4. Osteoarthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Osteoarthritis Late-Stage Products (Phase-III)
7. Osteoarthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteoarthritis Discontinued Products
13. Osteoarthritis Product Profiles
14. Osteoarthritis Key Companies
15. Osteoarthritis Key Products
16. Dormant and Discontinued Products
17. Osteoarthritis Unmet Needs
18. Osteoarthritis Future Perspectives
19. Osteoarthritis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Osteoarthritis Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
